Background: Ovarian cancer, particularly in advanced stages, requires cytoreductive surgery followed by chemotherapy. A significant proportion of patients are elderly, yet older women are often treated with non-standard regimens despite a lack of consistent evidence linking age to prognosis. The aim of this study is to assess age-specific differences in treatment and survival outcomes for ovarian cancer in women aged 70 years or older.Methods: This retrospective study included ovarian cancer patients treated at the Hospital del Mar, Barcelona, between 2016 and 2022. Patients were stratified into two groups: <70 and ≥70 years. Clinical and pathological data were analyzed, and hazard ratios (HR) for overall survival (OS) and disease-free survival (DFS) were calculated using Cox proportional hazards regression models. Multivariate analysis was performed to compare outcomes.Results: A total of 110 patients were included (73 <70 years, 37 ≥70 years). Among the older group, 80.5% were diagnosed at advanced stages (III–IV), compared to 63% in the younger group (p= 0.012). Patients aged ≥70 were more likely to undergo interval surgery (p= 0.053) and receive non-standard treatment (p= 0.023). Complete cytoreduction was achieved in 95.8% of younger patients versus 81.3% of older patients (p= 0.024). Age ≥70 did not significantly impact DFS (p= 0.091), but OS was significantly worse in the older group (44.4% vs. 67.2%,p= 0.014).Conclusions: Older women (≥70 years) with ovarian cancer are more likely to be diagnosed at advanced stages, receive non-standard treatment, and achieve suboptimal cytoreduction compared to younger patients. While DFS was similar across age groups, older age was associated with worse OS, highlighting the need for age-tailored treatment strategies.
背景：卵巢癌，尤其是晚期患者，需接受肿瘤细胞减灭术后辅以化疗。相当比例的患者为老年女性，但尽管缺乏一致证据表明年龄与预后相关，老年患者常接受非标准化疗方案。本研究旨在评估70岁及以上卵巢癌女性患者治疗与生存结局的年龄特异性差异。 方法：本回顾性研究纳入2016年至2022年间在巴塞罗那Hospital del Mar医院接受治疗的卵巢癌患者。将患者分为两组：<70岁组与≥70岁组。分析临床与病理学数据，采用Cox比例风险回归模型计算总生存期与无病生存期的风险比，并通过多变量分析比较治疗结局。 结果：共纳入110例患者（<70岁组73例，≥70岁组37例）。高龄组中80.5%确诊时为晚期（III–IV期），年轻组为63%（p=0.012）。≥70岁患者更可能接受间歇性肿瘤细胞减灭术（p=0.053）与非标准化疗（p=0.023）。年轻组完全肿瘤细胞减灭率达95.8%，高龄组为81.3%（p=0.024）。年龄≥70岁对无病生存期无显著影响（p=0.091），但高龄组总生存期显著更差（44.4% vs. 67.2%，p=0.014）。 结论：与年轻患者相比，≥70岁卵巢癌女性更易在晚期确诊、接受非标准化疗且肿瘤细胞减灭效果欠佳。尽管各年龄组无病生存期相似，但高龄与总生存期降低相关，这凸显了制定个体化年龄适配治疗策略的必要性。
Influence of Age on Treatment and Prognosis in Ovarian Cancer Patients
肿瘤(癌症)患者之家